Research
Hormonal
Incretin combination therapies are being developed for the treatment of nonalcoholic fatty liver disease (NAFLD) in patients with diabetes.
Practitioners should consider the potential of incretin therapies for managing NAFLD in diabetic patients.
StrongSupportsmedium confidence
Incretin combination therapies are being developed for treatment of type 2 diabetes and research has moved to test their usefulness in NAFLD.
Why this rating
The claim is based on a review of the literature.
Source
Looking ahead to potential incretin combination therapies for nonalcoholic steatohepatitis in patients with diabetes
Lucia Brodosi et al. · Expert Opinion on Pharmacotherapy · 2023
DOI 10.1080/14656566.2023.2208746
reviewCited 7×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →